GLAND — Gland Pharma Income Statement

0.000.00%

Last trade - 00:00

HealthcareAdventurousMid CapHigh Flyer

Annual income statement for Gland Pharma, fiscal year end - March 31st, INR millions except per share, conversion factor applied.

	2022 March 31st	2023 March 31st	2024 March 31st	2025 March 31st	2026 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	PRESS
Standards:	IAS	IAS	IAS	IAS	—
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	44,007	36,246	56,647	56,165	64,307
Cost of Revenue
Gross Profit	22,514	18,913	34,334	34,776	41,877
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	30,007	28,030	46,762	47,254	52,491
Operating Profit	14,000	8,216	9,885	8,911	11,815
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	16,186	10,546	11,325	10,627	14,646
Provision for Income Taxes
Net Income After Taxes	12,117	7,810	7,725	6,985	10,273
Net Income Before Extraordinary Items
Net Income	12,117	7,810	7,725	6,985	10,273
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	12,117	7,810	7,725	6,985	10,273
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	73.6	50.3	46.9	42.5	63.3
Dividends per Share